Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.46 SEK | -0.48% | +4.31% | +6.47% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.47% | 51.97M | |
+4.06% | 70.44B | |
+10.97% | 8.94B | |
-14.44% | 4.75B | |
+41.60% | 4.5B | |
+5.96% | 3.85B | |
+23.46% | 2.38B | |
-19.32% | 2.34B | |
-27.04% | 2.2B | |
+7.97% | 1.96B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Orexo Obtains First US Patent for Nasal Epinephrine Product